Literature DB >> 9499380

Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells.

F Matsuura1, M Ohta, Y A Ioannou, R J Desnick.   

Abstract

Human alpha-galactosidase A (alpha-Gal A) is the lysosomal glycohydrolase that cleaves the terminal alpha-galactosyl moieties of various glycoconjugates. Overexpression of the enzyme in Chinese hamster ovary (CHO) cells results in high intracellular enzyme accumulation and the selective secretion of active enzyme. Structural analysis of the N -linked oligosaccharides of the intracellular and secreted glycoforms revealed that the secreted enzyme's oligosaccharides were remarkably heterogeneous, having high mannose (63%), complex (30%), and hybrid (5%) structures. The major high mannose oligosaccharides were Man5-7GlcNAc2 species. Approximately 40% of the high mannose and 30% of the hybrid oligosaccharides had phosphate monoester groups. The complex oligosaccharides were mono-, bi-, 2,4-tri-, 2,6-tri- and tetraantennary with or without core-region fucose, many of which had incomplete outer chains. Approximately 30% of the complex oligosaccharides were mono- or disialylated. Sialic acids were mostly N -acetylneuraminic acid and occurred exclusively in alpha2, 3-linkage. In contrast, the intracellular enzyme had only small amounts of complex chains (7.7%) and had predominantly high mannose oligosaccharides (92%), mostly Man5GlcNAc2 and smaller species, of which only 3% were phosphorylated. The complex oligosaccharides were fucosylated and had the same antennary structures as the secreted enzyme. Although most had mature outer chains, none were sialylated. Thus, the overexpression of human alpha-Gal A in CHO cells resulted in different oligosaccharide structures on the secreted and intracellular glycoforms, the highly heterogeneous secreted forms presumably due to the high level expression and impaired glycosylation in the trans- Golgi network, and the predominately Man5-7GlcNAc2 cellular glycoforms resulting from carbohydrate trimming in the lysosome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499380     DOI: 10.1093/glycob/8.4.329

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  10 in total

Review 1.  Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Authors:  Patrick B Deegan
Journal:  J Inherit Metab Dis       Date:  2011-10-25       Impact factor: 4.982

2.  Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.

Authors:  Yunxiang Zhu; Xuemei Li; Alison McVie-Wylie; Canwen Jiang; Beth L Thurberg; Nina Raben; Robert J Mattaliano; Seng H Cheng
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

3.  Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

Authors:  Y A Ioannou; K M Zeidner; R E Gordon; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-12-13       Impact factor: 11.025

4.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

Authors:  C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

5.  Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.

Authors:  Maria Monticelli; Ludovica Liguori; Mariateresa Allocca; Andrea Bosso; Giuseppina Andreotti; Jan Lukas; Maria Chiara Monti; Elva Morretta; Maria Vittoria Cubellis; Bruno Hay Mele
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

6.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Authors:  T Chitlaru; C Kronman; M Zeevi; M Kam; A Harel; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

7.  Carboxyl-terminal truncations alter the activity of the human α-galactosidase A.

Authors:  Mariam Meghdari; Nicholas Gao; Abass Abdullahi; Erin Stokes; David H Calhoun
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

8.  Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders.

Authors:  Murtaza S Nagree; Tania C Felizardo; Mary L Faber; Jitka Rybova; C Anthony Rupar; S Ronan Foley; Maria Fuller; Daniel H Fowler; Jeffrey A Medin
Journal:  EMBO Mol Med       Date:  2022-03-17       Impact factor: 12.137

Review 9.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

10.  A protein chimera strategy supports production of a model "difficult-to-express" recombinant target.

Authors:  Hirra Hussain; David I Fisher; Robert G Roth; W Mark Abbott; Manuel Alejandro Carballo-Amador; Jim Warwicker; Alan J Dickson
Journal:  FEBS Lett       Date:  2018-07-03       Impact factor: 4.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.